Arrowhead Pharma Pres. & CEO Dr. Christopher Anzalone On Taking RNA Interference Beyond The Liver

Source: Bioprocess Online

Arrowhead Pharmaceuticals leader Christopher Anzalone, Ph.D. gives us the inside story on the stake his company claimed on the now re-burgeoning RNAi space, the indications his company is targeting beyond liver disease, and how it's addressing the development and process challenges that must be overcome to further progress RNAi beyond the liver.